T1期结直肠肿瘤的有蒂形态与不良结局风险降低相关
这项回顾性研究纳入荷兰14家医院2000至2014年诊断的1656例T1期结直肠癌患者,中位随访42.5个月。有蒂形态与不良结局风险降低独立相关(调整OR 0.59,95%CI 0.42-0.83,P=.003),在低风险组中转移、不完全切除和复发无显著差异,但高风险有蒂组的不完全切除和复发显著低于非有蒂组。
要点
- 有蒂T1期结直肠癌不良结局发生率为9.3%,非有蒂为16.6%。
- 有蒂形态独立降低不良结局风险(调整OR 0.59,95%CI 0.42-0.83)。
- 高风险有蒂组不完全切除和复发显著低于非有蒂组。
核心结论
- 在不良结局高风险的T1期结直肠癌人群中,有蒂形态与不良结局风险降低独立相关。
- 将肿瘤形态特征纳入风险评估可能有助于预测T1期结直肠癌患者的结局并识别最适合手术的患者。
研究设计与样本
- 回顾性研究,纳入2000至2014年荷兰14家医院诊断的1656例T1期结直肠癌患者。
- 中位随访时间为42.5个月(四分位距18.5-77.5个月)。
- 评估肿瘤形态与主要复合终点(不良结局)的关联,并调整临床变量、组织学变量、切缘和治疗方式。
主要发现
- 不良结局发生于有蒂T1期结直肠癌67/723例(9.3%),非有蒂155/933例(16.6%)。
- 有蒂形态独立与不良结局风险降低相关(调整OR 0.59,95%CI 0.42-0.83,P=.003)。
- 转移、不完全切除和复发分别见于有蒂组的5.8%、4.6%和3.9%,非有蒂组的10.6%、8.0%和6.6%。
- 有蒂形态独立与转移风险降低(调整OR 0.62,95%CI 0.41-0.94,P=.03)、不完全切除风险降低(调整OR 0.57,95%CI 0.36-0.91,P=.02)和复发风险降低(调整HR 0.52,95%CI 0.32-0.85,P=.009)相关。
- 低风险有蒂 vs 非有蒂T1期结直肠癌的转移(0.8% vs 2.9%,P=.38)、不完全切除(1.5% vs 0%,P=.99)和复发(1.5% vs 0%,P=.99)无显著差异。
关键数值与推荐
- 不良结局定义为淋巴结转移、远处转移、局部复发或残留组织。
- 次要终点为肿瘤转移、复发和不完全切除。
临床怎么用
- 作者认为,将肿瘤形态特征纳入风险评估可能有助于预测T1期结直肠癌患者的结局并帮助识别最适合手术的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Risk stratification for adverse events, such as metastasis to lymph nodes, is based only on histologic features of tumors. We aimed to compare adverse outcomes of pedunculated vs nonpedunculated T1 colorectal cancers (CRC). METHODS: We performed a retrospective study of 1656 patients diagnosed with T1CRC from 2000 through 2014 at 14 hospitals in The Netherlands. The median follow-up time of patients was 42.5 months (interquartile range, 18.5-77.5 mo). We evaluated the association between tumor morphology and the primary composite end point, adverse outcome, adjusted for clinical variables, histologic variables, resection margins, and treatment approach. Adverse outcome was defined as metastasis to lymph nodes, distant metastases, local recurrence, or residual tissue. Secondary end points were tumor metastasis, recurrence, and incomplete resection. RESULTS: Adverse outcome occurred in 67 of 723 patients (9.3%) with pedunculated T1CRCs vs 155 of 933 patients (16.6%) with nonpedunculated T1CRCs. Pedunculated morphology was independently associated with decreased risk of adverse outcome (adjusted odds ratio [OR], 0.59; 95% CI, 0.42-0.83; P = .003). Metastasis, incomplete resection, and recurrence were observed in 5.8%, 4.6%, and 3.9% of pedunculated T1CRCs vs 10.6%, 8.0%, and 6.6% of nonpedunculated T1CRCs, respectively. Pedunculated morphology was independently associated with a reduced risk of metastasis (adjusted OR, 0.62; 95% CI, 0.41-0.94; P = .03), incomplete resection (adjusted OR, 0.57; 95% CI, 0.36-0.91; P = .02), and recurrence (adjusted hazard ratio, 0.52; 95% CI, 0.32-0.85; P = .009). Metastasis, incomplete resection, and recurrence did not differ significantly between low-risk pedunculated vs nonpedunculated T1CRCs (0.8% vs 2.9%, P = .38; 1.5% vs 0%, P = .99; 1.5% vs 0%; P = .99). However, incomplete resection and recurrence were significantly lower for high-risk pedunculated vs nonpedunculated T1CRCs (6.5% vs 12.5%; P = .007; 4.4% vs 8.6%; P = .03). CONCLUSIONS: In a retrospective study of patients with T1CRC, we found pedunculated morphology to be associated independently with a decreased risk of adverse outcome in a T1CRC population at high risk of adverse outcome. Incorporating morphologic features of tumors in risk assessment could help predict outcomes of patients with T1CRC and help identify the best candidates for surgery.
引用
- Kessels K, Backes Y, Elias SG, et al. Pedunculated Morphology of T1 Colorectal Tumors Associates With Reduced Risk of Adverse Outcome. Clin Gastroenterol Hepatol. 2018. PMID: 30130623. doi:10.1016/j.cgh.2018.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。